natgillin/translations-raw huggingface dataset:
Figures 2 and 3 show the amino acid sequence of IL-2 in the PROLEUKIN™ product (SEQ ID NO: 1). 
Slike 2 i 3 prikazuju aminokiselinsku sekvencu od IL-2 u proizvodu PROLEUKINTM(SEQ ID NO: 1).
A combination for use according to claim 9 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska plućna fibroza (IPF), virusne infekcije dišnog sustava, virusne komplikacije respiratornih bolesti, aspergiloza, lišmenijaza, alergičko rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bolest bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, posthepatična neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
X is nitrogen or CR5 wherein R5 is hydrogen, halo or C1-4alkyl; provided that when R3 is hydroxy then X represents CH and R4 represents hydrogen; 
X je dušik ili CR5, gdje je R5 vodik, halogen ili C1-4alkil; uz uvjet da kada je R3 hidroksi, X predstavlja CH, a R4 predstavlja vodik;
The process according to claim 5, in which said effluent that for the most part contains hydrocarbons having more than 9 carbon atoms is sent into the fractionation e), and the another effluent that for the most part contains hydrocarbons having fewer than 9 carbon atoms is sent into the oligomerization d). 
Postupak prema patentnom zahtjevu 4 ili 5, naznačen time što se navedeni efluent koji se u najvećem dijelu sastoji od ugljikovodika i koji imaju više od 9 ili 12 ugljikovih atoma šalje u stupanj razdvajanja e), a efluent koji se u najvećem dijelu sastoji od ugljikovodika koji imaju 9 ili 12 ugljikovih atoma šalje se u stupanj oligomerizacije d).
Other omega-3 fatty acid 
Druge omega-3 masne kiseline
The compound of structure: or a pharmaceutically acceptable salt thereof. 
36. Spoj, naznačen time, da ima strukturu:
with a compound of formula (4) wherein PG is a nitrogen protecting group: 
sa spojem formule (4) [image] gdje je PG skupina koja štiti dušik;
For the creation of various surface patterns according to the invention, the section plane along which the block of wood is cut to a veneer can be freely selected. 
Radi stvaranja različitih površinskih uzoraka koji su u skladu s ovim izumom, ravnina sekcije, duž koje se reže blok od drva za dobivanje furnira, može biti slobodno odabrana.
Use according to claim 17, wherein the malignant neoplasia is selected from solid tumors, haematological tumors, and inherited cancers, comprising tumors of the breast, bladder, bone, brain, central and peripheral nervous system, colon, endocrine glands comprising thyroid and adrenal cortex, esophagus, endometrium, germ cells, head and neck, kidney, liver, lung, larynx and hypopharynx, mesothelioma, ovary, pancreas, prostate, rectum, renal, small intestine, soft tissue, testis, stomach, skin, ureter, vagina and vulva, Retinoblastoma and Wilms tumor, aggressive and indolent forms of leukemia and lymphoma, non-Hodgkins disease, chronic and acute myeloid leukemia (CML / AML), acute lymphoblastic leukemia (ALL), Hodgkins disease, multiple myeloma, T-cell lymphoma, myelodysplastic syndrome, plasma cell neoplasia, paraneoplastic syndromes, cancers of unknown primary site and AIDS related malignancies. 
Upotreba u skladu s patentnim zahtjevom 17, naznačena time što se zloćudne novotvorine bira između čvrstih tumora, hematoloških tumora, te nasljednih oblika raka, uključujući tumore dojke, mokraćnog mjehura, kostiju, mozga, središnjeg i perifernog živčanog sustava, debelog crijeva, endokrinih žlijezda, uključujući štitnjaču 1 koru nadbubrežne žlijezde, jednjaka, endometrija, germinativnih stanica, glave 1 vrata, bubrega, jetre, pluća, larinksa i hipofarinksa, mezoteliom, jajnika, gušterače, prostate, rektuma, bubrežnog tkiva, tankog crijeva, mekih tkiva, testisa, želuca, kože, uretera, vagine i vulve, retinoblastom i Wilmsov tumor, agresivne i indolentne oblike leukemije 1 limfoma, neHodgkinovu bolest, kroničnu i akutnu mijeloidnu leukemiju (CML/AML), akutnu limfoblastičnu leukemiju (ALL), Hodgkinovu bolest, multipli mijelom, T-stanični limfom, mijelodisplastični sindrom, plazmacitne novotvorine, paraneoplastične sindrome, rak nepoznatog primarnog sijela i malignome povezane s AIDS-om.
The apparatus according to claim 9, wherein: the first piston part and the second piston part move co-axially and the piston seat cover is adapted to move in an axial direction with respect to the first piston part. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time da: se prvi dio klipa (110) i drugi dio klipa (120) pomiču koaksijalno i poklopac sjedišta klipa (130) je prilagođen da se pomiče u aksijalnom smjeru u odnosu na prvi dio klipa (110).
is a group of Formula (A): wherein: 
Rs je skupina Formule (A): gdje:
and R2 together with the nitrogen form a ring selected from the group consisting of azetidine, pyrrolidine, piperidine, piperazine, homopiperazine or morpholine, which ring may be unsubstituted or it may comprise one or more substituents, such as, e.g. a maximum of one or two substituents, e.g. selected from the group consisting of hydroxy, C1-6-alkyl (e.g. methyl), halogen (e.g. fluoro or chloro), C1-6-alkoxy (e.g. methoxy), C1-6-alkylthio, alkylsulphonyl, trifluoromethyl, trifluoromethylsulfonyl and C1-6-alkylcarbonyl. To further illustrate the invention, without limitation, the following embodiments of R3-R12 are within the scope of the invention, in particular for the compounds as the free base or salt thereof: 
R! i R* tvore zajedno s dušikom, prsten izabran iz grupe koja se sastoji od azetidina, pirolidina, piperidina, piperazina, homopiperazina ili morfolina, koji prsten može biti nesupstituiran ili može sadržati jedan ili više supstituenata kao npr. maksimalno jedan ili dva supstituenta, npr. izabrani iz grupe koja se sastoji iz C;.s-alkil (npr. metil) halogena (npr. fluor ili klor) C;.g-alkoksi (npr. metoks1), C;.s-alkiltio, alkilsulfonil, trifluorometilsulfonil i C; g-alkilkarbonil. Kako bi nadalje ilustrirali izum, bez da ga ograničimo, slijedeći oblici R*-R'" se nalaze unutar dometa izuma, pogotovo kao slobodna baza izuma i njegove soli.
A process according to claims 1-12 wherein the polymeric shell of the microcapsule is obtainable by reacting the first monomeric component with the second monomeric component by interfacial polymerization by polycondensation or by reacting the second monomeric component formed in situ with the first monomeric component. 
Postupak prema zahtjevima 1-11 naznačen time da polimerna ovojnica mikrokapsule se može dobiti reakcijom prve monomerne komponente s drugom monomernom komponentom interfacijalnom polimerizacijom pomoću polikondenzacije ili reakcijom druge monomerne komponente nastale in silu s prvom monomernom komponentom.
N-[4-((S)-3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide, and pharmaceutically-acceptable salts and/or solvates thereof. 
N-[4-((S)-3-benzilpirolidin-1-il)-2-metilkinolin-6-il]benzamid, i njihove farmaceutski prihvatljive soli i/ili njihovi solvati.
Method according to claim 1, wherein the slurry containing the PVPP particles and yeast from the fermented liquid is removed by means of kieselguhr filtration or membrane filtration. 
Postupak prema Zahtjevu 1, gdje se kaša koja sadrži PVPP čestice 1 kvasac uklanja iz fermentirane tekućine kieselguhr filtracijom ili membranskom filtracijom.
Item 6. The method according to item 5, wherein the method further comprises the step of applying moisture on the resin (5) in powder form. 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje metoda dalje sadrži korak nanošenja vlage na smolu u obliku praha.
The resultant solution was extracted with EtOAc (5 mL x 3). 
Rezultirajuća otopina je ekstrahirana sa EtOAc (5 mL x 3).
A pharmaceutical composition according to claim 6, wherein the coating agent is hypromellose. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je sredstvo za oblaganje hipromeloza.
an isotonising agent, and/or 
* humanizirano protutijelo, i/ili
The pharmaceutical composition of claim 1, wherein the total amount of the digestive enzyme in the composition is from about 10 to about 15% by weight. 
Kompozicija u skladu sa zahtjevom 1, naznačena time što je ukupna količina digestivnih enzima i kompoziciji od oko 4 do oko 20 % mase i što je najmanje jedan nosač mikrokristalna celuloza.
In order to make abuse possible, the corresponding dosage forms, such as tablets or capsules are comminuted, for example ground in a mortar, by the abuser, the active ingredient is extracted from the resultant powder using a preferably aqueous liquid and the resultant solution, optionally after being filtered through cotton wool or cellulose wadding, is administered parenterally, in particular intravenously. 
Da se omogući zlouporaba, zlorabitelj odgovarajuće oblike davanja, kao što su tablete ili kapsule usitni, na pr. stuca u mužaru, djelatnu tvar iz tako dobivenog praha ekstrahira prvenstveno pomoću vodene tekućine i nastalu otopinu, po potrebi nakon filtriranja kroz vatu ili staničevinu, primijeni parenteralno, osobito intravenozno.
In another aspect of the present invention the compound of at least one element of group IVB of the periodic table may be on an oxide and/or hydroxide form or a combination of the two. 
Metoda u skladu s patentnim zahtjevom 24, pri čemu je tvar barem jednog elementa grupe IVB periodičkog sustava u obliku oksida i/ili hidroksida ili njihova kombinacija.
the client is configured as apparatus according to claim 19 or 20; and/or the client comprises an apparatus according to claim 19 or 20. The system of claim 22, further comprising the set top box according to claim 21, wherein the set top box is connected to the client. 
Sustav u skladu s patentnim zahtjevom 22, naznačen time što: klijent je konfiguriran kao uređaj u skladu s patentnim zahtjevom 19 ili 20; i/ili klijent sadrži uređaj u skladu s patentnim zahtjevom 19 ili 20. 24. Sustav u skladu s patentnim zahtjevom 22, naznačen time što dodatno sadrži digitalni video prijemnik u skladu s patentnim zahtjevom 21, gdje je digitalni video prijemnik povezan s klijentom.
A method for making a host cell for production of at least two different antibodies, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first, a second, a third and a fourth CH3 domain-comprising polypeptide chain, wherein said first CH3 domain-comprising polypeptide chain comprises a human IgG CH3 domain that comprises a lysine (K) residue at amino acid position 366 according to the EU numbering system and wherein said second CH3 domain-comprising polypeptide chain comprises a human IgG CH3 domain that comprises an aspartic acid (D) residue at amino acid position 351 according to the EU numbering system, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Postupak za pripremu stanice domaćina za proizvodnju najmanje dva različita antitijela, pri čemu postupak sadrži korak uvođenja u navedenu stanicu domaćina sekvenci nukleinske kiseline koje kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizinski (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije, pri čemu navedene sekvence nukleinske kiseline su uvedene uzastopno ili istovremeno.
A GLYX peptide for use as in claim 1, wherein the effective amount is about 0.01 mg/kg to about 1000 mg/kg per day. 
GLYX-13 za primjenu u skladu sa zahtjevima 1 ili 2, naznačeno time da se GLYX-13 administrira u količini od 0.01 mg/kg do 1000 mg/kg na dan.
A compound of claim 1, or a pharmaceutically acceptable acid addition salt thereof, for use in the treatment of depression, bipolar disorder and anxiety in a mammal. 
Tvar iz patentnog zahtjeva 1, ili njena farmaceutski prihvatljiva sol dobivena adicijom kiseline, za uporabu u liječenju depresije, bipolarnog poremećaja 1 tjeskobe u sisavaca.
A method of detecting rotation of a container (12) during optical inspection for commercial variations, in which light is analyzed after interaction with the container (12) to identify fluctuations in the light indicative of actual rotation of the container during inspection, said method including the steps of: 
Postupak detekcije zakretanja spremnika (12) tijekom optičkog pregleda na komercijalne varijacije, u kojem se svjetlo analizira nakon međudjelovanja sa spremnikom (12), radi identificiranja fluktuacija svjetla indikativnih za stvarno zakretanje spremnika tijekom pregleda, gdje se navedeni postupak sastoji u:
The process according to claim 9, wherein the platinum is used in an amount of 0.018 to 0.027 mol per 1 mol of 7-ethylcamptothecin, in the form of a hydrogenation catalyst, formed by platinum on an activated carbon with a platinum content 5%. 
Postupak prema patentnom zahtjevu 9, naznačen time što platinu se upotrebljava u količini od 0,018 do 0,027 mol, po mogućnosti 0,020 do 0,025 mol, na 1 mol 7-etilkamptotecina, u obliku hidrogenacijskog katalizatora, kojeg čini platina na aktiviranom ugljiku, uz količinu platine od 5 %.
The cells for the use according to any one of claims 1 and 4 to 5, wherein culturing conditions of said three-dimensional culture comprise an adherent material selected from the group consisting of a polyester and a polypropylene. 
Stanice ili proizvodni artikl, namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 1 7 do 10, naznačeni time što uvjeti uzgoja u navedenoj trodimenzionalnoj kulturi uključuju adherentni materijal, koji se bira iz skupine koju čine poliester i polipropilen.
An antibody, capable of binding a stabilized soluble a-synuclein oligomer, the stabilized soluble a-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the a-synuclein, wherein the antibody is produced from the stabilized soluble a-synuclein oligomer, wherein the stabilized soluble a-synuclein oligomer comprises a-synuclein of a sequence selected from SEQ ID NOs: 1-8, and wherein the stabilized soluble a-synuclein oligomer is stabilized by cross-linking with a protein cross-linking agent or by binding to a stabilizing agent. 
Antitijelo, sposobno vezati stabilizirani topivi oligomer a-sinukleina, stabilizirani topivi oligomer a-sinukleina ima nižu stopu formiranja u netopivi agregatni oblik nego nestabilizirani topivi oligomer a-sinuklema, pri čemu je antitijelo proizvedeno iz stabiliziranog topivog oligomer a-sinukleina, pri čemu stabilizirani topivi oligomer asinukleina sadrži a-sinuklein sekvence odabrane iz SEQ ID NOs: 1-8, 1 pri čemu je stabilizirani topivi oligomer asinukleina stabiliziran umrežavanjem s agensom za umrežavanje proteina ili vezanjem na agens za stabiliziranje.
positioning the ejector based on a dimension of the contents of the respective oven of the plurality of ovens to bias the contents of the respective oven against movement during transit of the vehicle. 
pozicioniranje uređaja za izbacivanje na temelju dimenzija sadržina iz štednjaka, u svrhu uravnoteženja sadržaja u štednjaku, za sprečavanje njegovog pomicanja za vrijeme putovanja vozila (240).
Thus, the present invention provides compounds with characteristics that are distinct from other drugs in its class such as rapamycin. 
Prema tome, ovaj izum daje spojeve čija su svojstva različita od ostalih lijekova u toj grupi, kao što je rapamicin.
The system according to claim 1, wherein said transmitting circuitry is adapted to transmit said signal such that the characteristic signal pattern does not coincide with any of the reference points repetitively occurring in said phase voltages of said polyphase power line. 
- navedeni krug (1, 3, 32) za prijenos signala je prilagođen za prijenos navedenog signala tako da se karakterističan oblik signala ne poklapa niti s bilo kojom referentnom točkom koja se ponavljajući pojavljuje u navedenim faznim naponima navedene polifazne linije.
Locomotor activity was determined during a 10 minute period using a video image analyzer (Videotrack, View Point, Lyon, France). 
Lokomotorno djelovanje je određeno za vrijeme razdoblja od 10 minuta pomoću video analizatora (Videotrack, View Point, Lyon, France).
A compound of either of the following formulae: wherein R1 is selected from the group consisting of OR2 and NR3R4, and R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, and heteroaryl groups. 
"R! gdje R, se bira iz skupine koju čine OR, i NR:Ru, gdje svakog od Rx, R3 i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
Compound A Form A of claim 1 for use in a method for treating, pretreating, or delaying onset or progression of anemia. The compound for use of any one of claims 7 to 12, wherein: 
Spoj A Oblika A prema zahtjevu 1 naznačen time što je za upotrebu u postupku liječenja, primjeni neposredno prije liječenja, ili odlaganja početka ili napredovanja anemije.
denotes that C20 is substituted with —OH or ═O, and denotes that C16 is substituted with —H, 
naznačuje da je C20 supstituiran s –OH ili =O, i naznačuje da je C16 supstituiran s –H,
According to one embodiment, the at least one viscosity increasing agent is selected from cellulose derivatives, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, or methylcellulose, poloxamers, from gums, guar gum, tragacanthe gum, acacia gum, xanthane gum, alginic derivatives, alginic acid, sodium alginate, polyvinylpyrrolidone, from silicates, bentonite, laponite, veegum, for example hydroxyethylcellulose, and is for example in an amount of from 0 to 15% w/V, e.g. 
celuloze, hidroksietilceluloze, hidroksipropilceluloze, hidroksipropilmetilceluloze, ili metilceluloze, poloksamera, od guma, guar gume, tragantove gume, gume akacije, ksantan gume, gelan gume, alginskih derivata, alginske kiseline, natrijum alginata, polivinilpirolidona, od silikata, bentonita, laponita, veegum, specifičnije od ne-ionskih poloksamera, polivinilpirolidona i celulozni eteri, u količini od 0 do 15% tež/vol, npr.
recovering the antibody molecule from the cell culture. A kit comprising: 
(c) dobivanje molekule protutijela iz stanične kulture.
Furthermore, in recent years the strength of the wirelines generally has increased. 
Nadalje, posljednjih godina je u općem slučaju porasla otpornost žičane veze.
The pharmaceutical composition for use in treatment of neoplasia of claim 20, said composition further comprising a cytokine selected from the group consisting of IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran 1z skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
The pharmaceutical composition of any preceding claim wherein the crosslinked amine polymer has a proton binding capacity of at least 10 mmol/g and a chloride ion binding capacity of at least 10 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCl at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, gdje je umreženi aminski polimer sa kapacitetom vezanja protona od najmanje 10 mmol/g i kapacitetom vezanja kloridnih iona od najmanje 10 mmol/g, u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM ECI, pri pH 1,21 na 3TC.
The composition for use according to claim 3, wherein the antibiotic is selected from the group consisting of quinolone antibiotics, penicillin antibiotics, macrolide antibiotics, cephalosporin antibiotics, sulfa antibiotics, and beta-lactamase inhibitors. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se antibiotik bira iz skupine koju čine kinolonski antibiotici, penicilinski antibiotici, makrolidni antibiotici, cefalosporinski antibiotici, sulfa antibiotici, te inhibitori B-laktamaze.
The antitumor agent for use according to any one of claims 1 to 3, wherein one cycle of an administration schedule, in which, in a period of 28 days, a combination drug containing a,a,a-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione hydrochloride in a molar ratio of 1:0.5 is administered on Days 1 to 5 and on Days 8 to 12, and CPT-11 is administered on Days 1 and 15, is repeated once or twice or more times. 
Antitumorni agens za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1 do 3, gdje jedan ciklus rasporeda administracije, u kojem, u periodu od 28 dana, kombinirani lijek koji sadrži o,a,a-trifluorotimidin i 5-kloro-6-(2- iminopirolidin-1-il)metil-2,4(1H,3H)-pirimidindion hidroklorid u molarnom odnosu od 1:0.5 je administriran na Dane 1 do 5 i na Dane 8 do 12, i CPT-11 je administriran na Dane 1 i 15, je ponovljen jednom ili dva puta ili više puta.
The method of claim 16, wherein communicating the converted data to a remote computer comprises wirelessly communicating the converted data to a remote computer. 
Postupak sukladno zahtjevu 16, naznačen time, da prijenos konvertiranih podataka do udaljenog računala obuhvaća bežično prenošenje konvertiranih podataka do udaljenog računala.
An international patent application publication No. 
Broj europske prijave patenta:
a light chain variable domain (VL) of sequence SEQ ID No. 35, wherein said sequence SEQ ID No. 35 comprises at least 1 back-mutation selected from the residues 22, 53, 55, 65, 71, 72, 77 and 87. 
77, 79, 82 1 95; te b) varijabilnu domenu lakog lanca (VL) sekvencije SEQ ID br. 35, pri čemu rečena sekvencija SEQ ID br.
mixing the mineral composition according to claim 1 with water, thereby obtaining a fluid composition, 
miješanje mineralnog sastava prema bilo kojem od prethodnih zahtjeva s vodom tako da se dobije fluidni sastav,
The storage part 1 is provided with an additional inside front wall 7, while the outside front wall 8 of the storage part 1 is hinged. 
Spremišni dio 1 ima dodatni unutarnji prednji zid 7, dok je vanjski prednji zid 8 spremišnog dijela 1 preklopni.